跳至主要内容
临床试验/CTRI/2022/01/039738
CTRI/2022/01/039738尚未招募未知

A Prospective, Randomized, Parallel Group, Double Blind, Multicentric, Active Controlled, School Based Study to Evaluate the Efficacy and Safety Of Albendazole 400 mg & Ivermectin 3 mg/6 mg/ 12 mg combination vs Albendazole 400 mg in reduction of Soil-transmitted helminth infections in children

MANKIND PHARMA LTD0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Children in the age group of 6-15 years attending the schools
  • selected for the study.
  • 2. Parents willing to provide written informed consent to
  • participate in the trial and assent from children aged 7 and

排除标准

  • 1. Presence of any major severe systemic illness, chronic severe
  • 2. History of epileptic disorders, visual disturbances, chronic
  • 3. Current use of anti-epileptics
  • 4. Any subject febrile on the day of enrolment
  • 5. Presence of any acute illness, vomiting, headache etc. on the
  • day of enrolment
  • 6. Recent use of anti-helmintic drugs through governmentâ??s mass
  • drug administration program within the past 3 months in both
  • the study subject and any household contacts
  • 7. Known allergy to the study medications
  • 8. Current use of drugs known to have pharmacological interaction with Albendazole or Ivermectin

研究者

发起方
MANKIND PHARMA LTD

相似试验